Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Immune Checkpoint Inhibitor
100%
Immune-Related Adverse Events
100%
Lung Cancer
66%
Melanoma
66%
Lymphocyte
50%
Malignant Neoplasm
33%
Disease Burden
33%
Biological Marker
16%
Patient-Data
16%
Progression Free Survival
16%
Overall Survival
16%
Proportional Hazards Model
16%
Retrospective Study
16%
Fisher Exact Test
16%
Chi Square Test
16%
Log Rank Test
16%
Ipilimumab
16%
Nivolumab
16%
Diseases
16%
Keyphrases
Immune-related Adverse Events (IrAEs)
100%
Immune Checkpoint Inhibitors
100%
Lung Cancer
30%
Hematological Parameters
30%
Disease Burden
20%
Lymphocytes
20%
Clinical Parameters
20%
Melanoma
20%
Rationing
20%
Dual Agent
20%
Patient Data
10%
Progression-free Survival
10%
Life-threatening
10%
Cancer Types
10%
Overall Survival
10%
Two-dose
10%
Cox Proportional Hazards Model
10%
Lung Cancer Patients
10%
Potential Predictors
10%
Fisher's Exact Test
10%
Clinical Factors
10%
Hospital Admission
10%
Melanoma Patients
10%
Absolute Lymphocyte Count
10%
Log-rank Test
10%
Metastatic Site
10%
Melanoma Cancer
10%
Ipilimumab
10%
Pearson's chi-square Test
10%
Cancer Institute
10%
Treatment Stage
10%
Immune Checkpoint Therapy
10%
Cancer Lung
10%
Biochemistry, Genetics and Molecular Biology
Immune Checkpoint Inhibitor
100%
Disease Burden
33%
Lymphocyte
33%
Overall Survival
16%
Progression Free Survival
16%
Retrospective Study
16%
Patient Coding
16%
Lymphocyte Count
16%
Ipilimumab
16%